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Several mutants of the Bacillus thuringiensis Cry1Ca toxin
affected with regard to specific activity towards Spodoptera exigua
were studied. Alanine was used to replace single residues in loops
2 and 3 of domain II (mutant pPB19) and to replace residues 541–
544 in domain III (mutant pPB20). Additionally, a Cry1Ca
mutant combining all mutations was constructed (mutant pPB21).
Toxicity assays showed a marked decrease in toxicity against S.
exigua for all mutants, while they retained their activity against
Manduca sexta, confirming the importance of these residues
in determining insect specificity. Parameters for binding to the
specific receptors in BBMV (brush border membrane vesicles) of
S. exigua were determined for all toxins. Compared with Cry1Ca,
the affinity of mutant pPB19 was slightly affected (2-fold lower),
whereas the affinity of the mutants with an altered domain III
(pPB20 and pPB21) was approx. 8-fold lower. Activation of
Cry1Ca protoxin by incubation with S. exigua or M. sexta BBMV
revealed the transient formation of an oligomeric form of Cry1Ca.
The presence of this oligomeric form was tested in the activation
of the different Cry1Ca mutants, and we found that those mu-
tated in domain II (pPB19 and pPB21) could not generate the
oligomeric form when activated by S. exigua BBMV. In contrast,
when oligomerization was tested using BBMV prepared from
M. sexta, all of the Cry1Ca mutants showed the formation of a
similar oligomeric form as did the wild-type toxin. Our results
show how modification of insect specificity can be achieved by
manipulation of different parts of the toxin structure involved in
different steps of the mode of action of B. thuringiensis toxins.
Key words: bacterial toxin, Manduca sexta, mode of action,
protoxin activation, toxin oligomerization, toxin receptor binding.
INTRODUCTION
Strains of Bacillus thuringiensis, a Gram-positive entomopath-
ogenic bacterium, produce different kinds of crystal inclusions
during sporulation. These crystal inclusions are composed of one
or various Cry proteins (also called δ-endotoxins). Some of these
proteins are highly toxic to certain insects, but they are harmless
to most other organisms, including wildlife and beneficial insects
[1,2].
The mode of action of B. thuringiensis Cry1 and related proteins
follows, after ingestion by the insect, a complex process of
multiple steps. These include: (i) solubilization of the crystal to
release the Cry proteins in their protoxin form, (ii) activation of the
protoxins by midgut proteases to their active form, (iii) binding of
the toxin to midgut receptors, and (iv) pore formation in the brush
border cell membranes, eventually killing the insect. Recently, an
intermediate step has been suggested to link protoxin activation
and binding to specific receptors. This step would include the
interaction of the not fully activated toxin with the midgut of
the insect through specific binding sites involved in the activation
and oligomerization of the toxin. Oligomeric forms have been
suggested, in that model, as being responsible for insertion into
the membrane and pore formation [3].
Several midgut epithelial membrane proteins have been
reported to be specific binding sites for Cry1A toxins. In the most
studied insect, Manduca sexta, Cry1A toxins showed binding
to a 120 kDa aminopeptidase and to a 210 kDa cadherin-like
protein. Also in M. sexta, an aminopeptidase N has been isolated
through its affinity for Cry1Ca toxin [4]. In addition, silencing of
the expression of a member of the aminopeptidase N family in
Spodoptera litura larvae decreased their susceptibility to Cry1Ca
[5]. These data together suggest a strong similarity (although with
some differences) in the modes of action of Cry1A and Cry1C
toxins.
The crystal structures of several trypsin-activated Cry proteins
(Cry1Aa, Cry3Aa, Cry3Bb and Cry2Aa) have been elucidated
[6–9], revealing a similar three-domain structure. The N-terminal
domain I consists of seven α-helices, and is thought to be
responsible for toxin insertion into the cell membrane, leading to
pore formation. The more variable domain II has been shown
to be involved in the interaction with toxin binding sites in the
midgut of the insect, playing an important role in determining
insect specificity. Interaction of domain II with the binding sites
is thought to take place through three main loops identified in
its structure. Mutagenesis of some residues localized in these
loops leads to reduced binding and, as a consequence, decreased
toxicity (reviewed in Schnepf et al. [1]). Domain III is a
β-sandwich with a jelly roll topology. Domain III exchange in
hybrid toxins has resulted in new toxins with altered specificity
and increased toxicity compared with the parental toxins,
revealing the importance of domain III in specific binding to
putative receptors and specificity [10,11]. For instance, hybrid
toxins containing domains I and II of Cry1Ea or Cry1Ab and
domain III of Cry1Ca (G27 and H04 respectively) showed an
increase in activity against Spodoptera exigua compared with
Cry1Ab or Cry1Ea [10]. Furthermore, domain III was shown to
be responsible for the N-acetylgalactosamine-inhibited binding
of Cry1Ac to M. sexta aminopeptidase N [13,14].
Yamamoto and Dean [15] reported that Cry1Ca toxin
containing a substitution in the hypothetical loop 2 (Gln374Ala)
together with a substitution in loop 3 (Thr440Ala), both in domain
II, had reduced toxicity against S. exigua. They also showed
Abbreviations used: BBMV, brush border membrane vesicles; GI, growth inhibition; LC50, concentration causing 50% mortality.
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that such a mutant competes less effectively with biotin-labelled
Cry1Ca for binding to S. exigua BBMV (brush border membrane
vesicles). Alanine substitution of residues 541–544 of domain III
of Cry1Ca in the hybrid G27 toxin abolished the activity of this
hybrid against S. exigua, but not against M. sexta [16]. These
results suggested an important role for domain III, as well as
for domain II, in the mode of action of Cry1Ca, including insect
specificity.
In the present study, we took a more detailed look at the effects
of mutations in domain II and/or domain III on the target insect
specificity and mode of action of Cry1Ca. In particular, we studied
how these different mutations can modify the interaction of the
toxin with different elements involved in the complex process of
binding to the midgut receptors. Additionally, for the first time,
we demonstrated that mutations in domain II loops affect, in an
insect-specific manner, the ability of the toxin to form oligomers.
EXPERIMENTAL
Mutagenesis and protein isolation
Cry1Ca mutants were constructed by introduction of the
mutations Gln374Ala and Thr440Ala (domain II mutant; pPB19),
Ser541Ala, Thr542Ala, Gly543Ala and Val544Ala (domain III mutant;
pPB20), or all mutations combined (mutant pPB21), in the cry1Ca
gene in expression plasmid pBD150 [16], using the QuickChange
mutagenesis kit (Stratagene, Amsterdam, The Netherlands).
Wild-type Cry1Ca and mutant protoxins were expressed in
Escherichia coli strain XL-1 Blue, extracted, solubilized and
trypsin treated as described previously [16]. Briefly, each 1 g
of cell culture expressing the different toxins was resuspended in
3 ml of lysis buffer (50 mM Tris/HCl, pH 8.0, 5 mM EDTA,
100 mM NaCl) by vigorous shaking, and then 800 µg of
lysozyme was added per g of pellet. After incubation at room
temperature for 20 min, deoxycholic acid was added to a final
concentration of 1 mg/ml and incubated at 37 ◦C for 30 min. Then
DNase I was added to a final concentration of 50 µg/ml and
incubation at 37 ◦C was continued for another 30 min. The mix-
ture was clarified by centrifugation at 40 000 g for 20 min. Pellets
containing the protoxin inclusion bodies were washed several
times with washing buffer (20 mM Tris/HCl, pH 8.0, 5 mM
EDTA, 100 mM NaCl). Protoxin was solubilized by incubation
of the inclusion bodies at 37 ◦C in solubilization buffer (50 mM
sodium carbonate, pH 10.0) containing 10 mM dithiothreitol.
After at least 2 h of solubilization, soluble protoxin was separated
from the insoluble fraction by centrifugation at 40 000 g for
20 min. Then the pH of the solution was lowered to pH 9 using
1 M Tris/HCl, pH 8.0, and 0.2% (w/v) streptomycin was added
and incubated for 1 h on ice. When necessary, activation of
protoxin was performed by adding trypsin at a ratio of 1:10
(trypsin/protoxin, w/w) and incubating for 2 h at 37 ◦C. Protoxins
and trypsin-activated toxins were dialysed overnight against
50 mM sodium hydrogen carbonate, pH 9.0, 150 mM NaCl.
Toxins for binding assays were purified by anion-exchange
chromatography. Activated toxins were dialysed against Tris/
NaCl buffer (20 mM Tris/HCl, 150 mM NaCl, pH 9.0) overnight
at 4 ◦C. The dialysed solution was filtered and loaded on
to a MonoQ HR 5/5 anion-exchange column (FPLC system;
Pharmacia, Uppsala, Sweden) equilibrated previously with
Tris/NaCl buffer. Toxin was eluted from the column by increasing
the NaCl concentration. For iodine labelling of Cry1Ca, an ad-
ditional purification step was performed, following the procedure
described in Zhao et al. [17], to remove adsorbed protoxin
fragments that block iodination.
Insect bioassays
Trypsin-activated toxins were assayed by diet surface conta-
mination of a solid artificial diet. Neonate larvae of S. exigua and
1-day-old larvae of M. sexta were used for bioassays, and mortality
was scored after 6 days at 28 ◦C. The LC50 (concentration causing
50% mortality) and its 95% fiducial limits were estimated by
Probit analysis [18] of results from three or more independent
experiments using the POLO-PC program (LeOra Software,
Berkeley, CA, U.S.A.).
A GI (growth inhibition) assay was performed by diet surface
contamination with 2 µg/cm2 toxin. Early last-instar larvae of
S. exigua were weighed and allowed to eat contaminated diet.
After 48 h, larvae were weighed again and the percentage GI was
calculated as described previously [19]. Values of GI higher than
100 mean a loss of weight of the larvae during the assay.
BBMV preparation
BBMV to be used in binding assays were prepared according to
the method described by Wolfersberger [20]. The same protocol
was used for the preparation of the BBMV used in oligomerization
assays, except that EGTA was excluded from the buffers.
125I-labelling of Cry1Ca and binding assays
Cry1Ca was labelled with 125I using Iodo-beads® reagent
(Pierce Biotechnology, Rockford, IL, U.S.A.) following the
manufacturer’s recommendations. The specific radioactivity of
labelled Cry1Ca was 0.57 mCi/mg, as estimated by sandwich
ELISA. To determine specificity of binding and to select the
concentration of BBMV for competition assays, BBMV from
S. exigua (0–0.3 mg of total vesicle protein/ml) were incubated
with 710 pM 125I-Cry1Ca in 100 µl of PBS containing 0.1%BSA
at room temperature for 60 min. 125I-Cry1Ca bound to BBMV
was separated from free toxin by centrifugation at 16 000 g at
4 ◦C for 10 min. The pellet was washed twice with 500 µl of ice-
cold PBS/BSA. The radioactivity in the pellet was then measured
in a 1282 Compugamma CS Universal gamma counter (LKB-
Wallac Pharmacia, Turku, Finland) and taken as total binding.
Non-specific binding was estimated by adding a 1000-fold excess
of unlabelled toxin to the reaction mixture. Specific binding
was calculated as the difference between total and non-specific
binding.
For competition assays, increasing amounts of unlabelled wild-
type Cry1Ca, pPB19, pPB20 or pPB21 toxins were added to the
reaction mixture containing 125I-Cry1Ca and 100 µg/ml BBMV
in PBS/BSA. The estimation of dissociation constant (Kd) and
binding site concentration (Rt) was performed with the LIGAND
software package [21]. The parameter Kd refers to the apparent
dissociation constant and not to the true equilibrium dissociation
constant, since the binding of Cry proteins to BBMV is a two-
step process involving reversible plus irreversible binding [22].
Statistical tests (Student’s t test) were performed and charts made
using GraphPad Prism version 4.00 for Windows (GraphPad
Software, San Diego, CA, U.S.A.). Binding experiments were
independently performed at least twice.
Biotin labelling of Cry1Ca and binding assays
Cry1Ca was labelled with biotin using biotin N-hydroxy-
succinimide ester (Boehringer) as described previously [23]. For
binding experiments, BBMV (10 µg of protein) were mixed with
1 ng of biotin-labelled toxin and increasing amounts of unlabelled
Cry1Ca (1, 10, 100 and 1000 ng) in 50 µl of BBS (100 mM so-
dium borate, 150 mM NaCl, pH 8.0) containing 0.1%Tween-20.
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After incubation for 1 h at room temperature, vesicles were sep-
arated from unbound toxin by centrifugation, and the pellet was
washed once briefly with BBS/Tween. Subsequently, the pellets
containing BBMV proteins (including bound, labelled toxin)
were resuspended in 20 µl of 2% SDS in BBS. After heating
at 100 ◦C for 5 min, 200 µl of BBS was added to the sample
and the whole volume was transferred on to a nitrocellulose
membrane using a Minifold I Dot-Blot system (Schleicher &
Schuell BioScience). Bound, labelled toxin on the blot was de-
tected with streptavidin/peroxidase in a standard Western-blot
protocol.
Oligomerization assays
Oligomerization assays were performed with small modifications
of the method described by Rausell et al. [24]. Summarizing,
20 µl of solubilization buffer (50 mM sodium carbonate,
pH 10.0) containing 10 pmol of protoxin was incubated with
10 µl of solubilization buffer containing different concentrations
of BBMV (EGTA-free) from S. exigua or M. sexta for 15 or 30 min
respectively. The incubation was stopped by the addition of 5 µl
of a solution (10× concentrated) of Complete Protease Inhibitor
Cocktail (Roche Diagnostics). Samples were then centrifuged at
12 000 g for 20 min. The supernatant was mixed with SDS/PAGE
loading buffer and heated at 60 ◦C for 10 min, and proteins in the
sample were separated in an SDS/8%-PAGE gel. Monomeric and
oligomeric forms of Cry1Ca were detected using antibodies raised
against the Cry1Ca protoxin in a standard Western-blot protocol.
Toxin structure modelling
In order to obtain a three-dimensional model of Cry1Ca domain
III, we used the Web-based modelling service SWISS-MODEL
[25] with the structures of Cry3Aa (PDB code 1DLC) and Cry1Aa
(1CIY) as templates. For this purpose, Cry1Ea was modelled
in a first approach, and subsequently the hybrid G27 sequence
(containing Cry1Ca domain III) was added to the sequence align-
ment, which was then edited and resubmitted for modelling. For
visualization, a DeepView/Swiss-PdbViewer [26] generated script
was used as input for POV-ray [Persistence of Vision Raytracer
(version 3.6, 2004), Persistence of Vision Pty Ltd, Williamstown,
Victoria, Australia].
RESULTS
Toxicity of Cry1Ca mutants
Cry1Ca mutants were constructed in order to study the roles of
different amino acid residues in the mode of action of the toxin.
Mutant pPB19 was constructed to study the role of hypothetical
loops 2 and 3 of domain II. Alanine substitutions of Gln374
and Thr440 were chosen based on previous work that showed a
reduction in toxicity against S. exigua of this mutant [15]. Mutant
pPB20 was chosen to study the role of domain III by alanine
substitution of residues Ser541 to Val544. The same mutations in
the hybrid G27 (comprising domains I and II from Cry1Ea and
domain III from Cry1Ca) reduced toxicity against S. exigua,
but not against M. sexta [12]. Mutant pPB21 was generated by
combination of the mutations of pPB19 and pPB20. All three
mutants were highly expressed as inclusion bodies in E. coli,
similar to wild-type Cry1Ca. The stability of the different toxins
was compared by incubation for 24 h in the presence of S. exigua
midgut juice; activation and degradation patterns similar to those
of wild-type Cry1Ca toxin were observed (results not shown).
Bioassays of the wild-type and mutant toxins on neonate
larvae of S. exigua revealed a biological effect of the mutations.
Table 1 Toxicity of Cry1Ca and its mutant towards S. exigua and M. sexta
larvae
LC50 values were measured for neonate larvae; values in parentheses are 95 % fiducial limits.
GI was measured at 2000 ng/cm2 toxin for last-instar larvae; values are means +− S.E.M.
S. exigua M. sexta
Toxin LC50 (ng/cm2) GI (%) LC50 (ng/cm2)
Cry1Ca 68 (47–88) 110.8 +− 0.6 123 (94–152)
pPB19 2350 (1450–4101) 27.2 +− 4.9 116 (90–145)
pPB20 1985 (1414–2693) 51.0 +− 5.1 80 (61–100)
pPB21 7836 (5556–11 300) 8.2 +− 6.5 85 (60–110)
Table 2 Dissociation constant (K d) and concentration of binding sites (Rt)
estimated from competition experiments performedwith 125I-labelled Cry1Ca
and BBMV from S. exigua
Parameter values for Cry1Ca were obtained from homologous competition experiments.
For pPB19, pPB20, and pPB21, parameters were obtained from heterologous competition
experiments with 125I-Cry1Ca. R t is expressed as pmol of binding sites per mg of total vesicle
protein. Values are means +− S.D. of at least two replicates.
Toxin K d (nM) Rt (pmol/mg of protein)
Cry1Ca 21.0 +− 1.9 18 +− 3
pPB19 42 +− 4 13.1 +− 0.4
pPB20 149 +− 16 14 +− 3
pPB21 177 +− 4 15.6 +− 0.4
In agreement with previous results, where the above-described
substitutions were shown to affect toxin activity, mutants pPB19
and pPB20 showed 35- and 30-fold decreases respectively in
toxicity towards S. exigua (Table 1). A significantly stronger effect
was detected when domain II and domain III substitutions were
combined in the mutant pPB21: this mutant showed a 115-fold
decrease in toxicity towards S. exigua (Table 1). No significant
differences in toxicity among Cry1Ca and its mutants were
detected when they were assayed against M. sexta larvae (Table 1).
A decrease in the activity of the mutants was also detected for
last-instar larvae of S. exigua, confirming that any change in the
mode of action conferred by the mutations is maintained in
the older larvae, used subsequently for molecular studies. Com-
pared with the Cry1Ca wild-type toxin, GI expressed as per-
centage was reduced for all three mutants, with the pPB21 mutant
having the lowest toxicity (Table 1).
Effects of mutations on binding to S. exigua BBMV
Competition of 125I-Cry1Ca with unlabelled Cry1Ca (‘homolog-
ous’) and its mutants (‘heterologous’) was performed in order
to establish the effects of the mutations on binding to S. exigua
BBMV. Binding parameters such as dissociation constant (Kd) and
binding site concentration (Rt) were obtained for Cry1Ca and its
mutants. Compared with Cry1Ca, the domain III mutants (pPB20
and pPB21) showed an approx. 8-fold decrease in affinity (higher
Kd value) for the S. exigua binding sites (Table 2 and Figure 1A).
The domain II mutant pPB19 showed a smaller, but statistically
significant (t test; P = 0.0078), increase in Kd (lower affinity).
An increase in the Kd value was also detected when comparing
pPB21 with pPB20, although in this case it was not statistically
significant (Table 2 and Figure 1A). These results indicate that the
mutations introduced in domain III affected binding to S. exigua
BBMV more drastically than those introduced in domain II.
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Figure 1 Effects of mutations in Cry1Ca on binding to S. exigua BBMV
Binding of labelled Cry1Ca to BBMV from Spodoptera exigua in the presence of increasing
concentrations of unlabelled competitor is shown. (A) Competition of 125I-Cry1Ca with
unlabelled Cry1Ca (; thick solid line), pPB19 (; broken line), pPB20 (H17009; thin solid line)
and pPB21 (; dotted line). (B) Competition of biotin–Cry1Ca with increasing concentrations
(1-, 10-, 100- and 1000-fold) of unlabelled Cry1Ca or Ppb19.
Competition of pPB19 for Cry1Ca binding sites was also
detected semi-quantitatively using biotin-labelled Cry1Ca (Fig-
ure 1B). An excess of non-labelled competitor (Cry1Ca and
pPB19) of 100× or 1000× reduced drastically the amount of
biotinylated Cry1Ca that bound to S. exigua BBMV. As occurred
in the competition experiments using 125I-Cry1Ca, in biotin-
labelling experiments pPB19 showed a lower affinity for Cry1Ca
binding sites than wild-type Cry1Ca. This is reflected by, at a
competitor concentration of 10- or 100-fold excess, a higher
intensity of the spots of biotinylated Cry1Ca in the competition
with pPB19 compared with the competition with unlabelled
Cry1Ca (Figure 1B).
Toxin oligomerization assays
Oligomeration of the Cry toxins prior to membrane insertion was
described recently as an important step in the mode of action
[3,24]. Additionally, the activation of protoxin in the presence of
BBMV or in the presence of a peptide mimicking the cadherin-
like protein promoted the formation of such a toxin oligomer
[3,24,28,29]. We decided to study these phenomena in the
Cry1Ca–S. exigua interaction and, if found, to check whether
it is altered with the mutants under study.
In Figures 2(A) and 2(B) we show a comparison of the
activation of Cry1Ca and pPB21 protoxins by incubation with dif-
ferent concentrations of S. exigua EGTA-free BBMV. Oligomeric
forms with a molecular mass greater than 250 kDa were detected
on immunoblots when the Cry1Ca protoxin was activated using
BBMV from S. exigua (Figure 2B, lanes 1–3). Oligomeric forms,
though present in the Coomassie Blue-stained gel, were not easily
visible because of their low concentration and the lower sensitivity
of Coomassie Blue staining compared with immunoblot detection
(Figure 2A). Incubation of Cry1Ca protoxin with different
amounts of S. exigua BBMV showed that the oligomer concen-
tration decreased with increasing BBMV concentration, con-
current with increased levels of fully activated toxin. Under
the experimental conditions used in this work, the activation of
Cry1Ca protoxin with 1 µg of S. exigua BBMV generated the
highest concentration of oligomeric forms (Figure 2B, lane 1).
Incubation of Cry1Ca protoxin with 10 µg of BBMV was enough
to fully activate most of the protoxin, reducing at the same time
the amount of the oligomer (Figure 2B, lane 3).
In order to establish whether some of the studied mutants
were affected with regard to toxin oligomerization, a similar
experiment was performed using mutant pPB21. Coomassie Blue
staining of proteins generated by activation of pPB21 protoxin
in the presence of S. exigua BBMV showed the same pattern
as obtained with Cry1Ca protoxin (Figure 2A). In contrast with
results with Cry1Ca, immunoblots revealed the absence of the
oligomeric form at all BBMV concentrations tested (Figure 2B,
lanes 4–6). During the activation of pPB21, as well as during
the activation of Cry1Ca, a molecule with an apparent molecular
mass of 100 kDa was detected at lower BBMV concentrations
Figure 2 Cry1Ca and pPB21 activation and oligomerization with S. exigua and M. sexta BBMV
Portions of 20 µl of solubilization buffer containing 10 pmol of Cry1Ca or pPB21 protoxin were incubated with 10 µl of solubilization buffer containing 1, 5 or 10 µg of BBMV proteins from
S. exigua (A and B) or M. sexta (C and D) for 15 or 30 min respectively. Proteins in the sample were separated by SDS/8 %-PAGE. Coomassie Brilliant Blue staining (A and C) and immunodetection
of Cry1Ca on a Western blot (B and D) were performed.
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Figure 3 Oligomer formation of Cry1Ca and its mutants by activation with S. exigua and M. sexta BBMV
Portions of 20 µl of solubilization buffer containing 10 pmol of Cry1Ca, pPB19, pPB20 or pPB21 protoxin were incubated with 10 µl of solubilization buffer containing 2 µg of BBMV from
S. exigua (A and B) or M. sexta (C and D) for 15 or 30 min respectively. Proteins in the sample were separated by SDS/8 %-PAGE. Coomassie Brilliant Blue staining (A and C) and immunodetection
of Cry1Ca on a Western blot (B and D) were performed. Lanes 5 and 10 contain Cry1Ca treated under the same conditions but in the absence of BBMV.
(Figure 2B, lanes 1, 2, 4 and 5), which probably corresponds to
an intermediate-activation form. The presence of this 100 kDa
band, however, was not correlated with the presence of the
oligomeric form (Figure 2B, lanes 4 and 5). Oligomer formation
of Cry1Ca was also studied by activation in the presence of
M. sexta BBMV (Figures 2C and 2D). Oligomeric forms of a
similar electrophoretic mobility were detected when Cry1Ca was
activated using BBMV from M. sexta (Figure 2D, lanes 4–6).
Similar to experiments using S. exigua BBMV, increasing concen-
trations of M. sexta BBMV also reduced the amount of the
oligomeric forms (Figure 2D).
Oligomer formation of Cry1Ca and its mutants was studied
further by activation of their respective protoxins with BBMV
prepared from S. exigua and M. sexta. Assays with S. exigua
BBMV revealed a lack of oligomer formation during activation
of the domain II mutant (pPB19) and of the combined domain II
and III mutant (pPB21) (Figure 3B, lanes 2 and 4 respectively),
but not of the domain III mutant (pPB20) (Figure 3B, lane 3).
Since pPB20 did not show an alteration in oligomer formation
compared with Cry1Ca, we can conclude that the mutations in
domain II of pPB19 and pPB21 are responsible for the absence
of oligomeric forms of these toxins. The presence or absence of
the oligomeric forms did not correlate with changes in the overall
activation pattern, which was similar for all. Coomassie Blue
staining revealed the same pattern of bands for all four toxins
(Figure 3A). In contrast, when oligomerization was tested using
BBMV prepared from M. sexta, all of the Cry1Ca mutants showed
similar behaviour to the wild-type toxin, not only in overall
activation pattern (Figure 3C), but also in the level of oligomer
formation (Figure 3D).
DISCUSSION
In the present study we have focused on changes in the Cry1Ca
primary structure that can lead to a change in insect speci-
ficity without completely abolishing insecticidal activity. We
constructed Cry1Ca mutant proteins containing mutations in do-
mains II and III and compared their toxicity against S. exigua and
M. sexta. Bioassay results showed that although these mutations
markedly reduced toxicity against S. exigua, they did not affect
toxicity against M. sexta. For a better understanding of the role of
these regions in determining insect specificity, we compared the
behaviour of the different mutants with that of wild-type Cry1Ca
toxin in three steps in the mode of action of Cry toxins: activation,
receptor binding and toxin oligomerization.
The importance of domain II (specifically loops 2 and 3) in
determining the toxicity against S. exigua has been documented
previously. Yamamoto and Dean [15] reported that the double
mutant Gln374Ala/Thr440Ala had reduced toxicity against S. exigua
(although no toxicity values were given). Residue Gln374 (domain
II) has also been shown to be important in determining the specific
toxicity of Cry1Ca against Aedes aegypti larvae (Diptera). The
mutation of Gln374Asn reduced toxicity towards A. aegypti without
affecting toxicity towards Spodoptera littoralis [30]. In contrast,
the mutation Gln374Glu reduced the binding capacity and toxicity
for both insect species.
We have shown that the reduced toxicity of pPB19 (domain
II mutant) against S. exigua does not seem to be due directly
to alterations in overall binding affinity, which was just 2-fold
lower than that of Cry1Ca. This result is in contrast with that
reported previously by Yamamoto and Dean [15], who showed a
complete lack of competition of this mutant for Cry1Ca binding
sites using biotin-labelled Cry1Ca. To discount the possibility
that the differences in these results were caused by differences
in the method employed, we also performed the competition
experiment using biotin-labelled Cry1Ca, and obtained results
that supported those obtained using 125I-Cry1Ca. We do not have
a definitive explanation for these differences in the findings of
the two studies. It is possible that the source of the S. exigua
colonies employed in the respective assays could account for the
discrepancy. Differences in affinity (Kd) of approx. 5-fold have
been described for different populations of Helicoverpa armigera
[31].
Regarding mutations affecting domain III, replacement by
alanine of residues Ser541 to Val544 was based on previous results,
where a hybrid toxin G27 (domains I and II from Cry1Ea and
domain III from Cry1Ca) containing such substitutions showed
a reduction in toxicity against S. exigua but not against M. sexta
[12]. These changes in Cry1Ca, resulting in mutant pPB20, also
had a marked effect on toxicity against S. exigua larvae, but not
against M. sexta, revealing the importance of these residues in
determining the specificity of Cry1Ca. Here, the decrease in
toxicity was correlated with a much greater reduction (approx.
7-fold) in the affinity for the Cry1Ca binding sites present in
BBMV from S. exigua. Our model of the three-dimensional
structure of Cry1Ca domain III shows that residues 541–544 are
probably part of a surface-exposed loop consisting of residues
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Figure 4 Predicted three-dimensional structure of domain III of Cry1Ca
Ribbon representation of a model of the three-dimensional structure of domain III of Cry1Ca.
Amino acid residues discussed in the text are labelled and represented with side chains and
backbone.
539–546 connecting two β-strands on the slightly concave outer
β-sheet (Figure 4). The location of a tryptophan residue, which
was shown previously to also be involved in specificity for
S. exigua, is also indicated [12]. Thus we have shown that, similar
to earlier results for binding of Cry1Ac to aminopeptidase N of
M. sexta [14], this region of domain III is involved in receptor
binding. Whereas the mutations in Cry1Ac had no apparent effect
on toxicity against M. sexta in bioassays [14], the mutations
reported here destroy activity against S. exigua. Activity against
M. sexta is not affected, indicating that decreased stability of the
mutant protein is not a likely explanation.
It has been described that activation of Cry1Ab with M. sexta
BBMV or a peptide mimicking cadherin-like protein (BTR)
promotes toxin oligomer formation, and that such oligomerization
is dependent on the interaction with a domain II loop 2 region
[29,32]. To test whether oligomerization could also be a step in
the mode of action of Cry1Ca, and whether it could be impaired
by some of the studied mutations, we first checked if Cry1Ca was
able to form oligomers during interaction with BBMV. We found
that, similarly to Cry1Ab and M. sexta BBMV, oligomer structures
were also observed with Cry1Ca and S. exigua BBMV. However,
pPB19 and pPB21 toxins (both with domain II mutations) were
not able to form oligomers when activated with S. exigua BBMV,
while pPB20 formed oligomers in a similar way to wild-type
Cry1Ca. The importance of this phenomenon in the mode of action
is reinforced by the observation that all mutants were equally
toxic as Cry1Ca against M. sexta and that oligomer formation
was not affected in any of them. Thus the mutations in pPB19
do not affect the capacity to form oligomers per se. From these
results, we can conclude: (i) changes in domain II loops, but not in
domain III, affect the interaction necessary for oligomer formation
of Cry1Ca in S. exigua, and (ii) these same changes do not affect
Cry1Ca oligomerization in M. sexta.
A previous study [33], in which residues in loop 2 of Cry1Ab
toxin were replaced by alanine, showed that mutant Phe371Ala had
reduced toxicity for M. sexta larvae. Competitions experiments
revealed that this mutant had similar binding parameters as
Cry1Ab, but dissociation binding experiments showed that the
percentage of irreversible binding (membrane insertion) was
lower. It would be interesting to determine whether this mutant is
affected in oligomer formation in M. sexta.
In another study, domain II and domain III of Cry1C were ex-
pressed separately. Binding experiments in Spodoptera littoralis
comparing the binding parameters of whole Cry1C and isolated
domain II showed that, of the overall number of binding sites
for Cry1C toxin, approx. 10% are domain II binding sites [34].
According to those results, specific changes in domain II would
hardly be reflected in overall binding, something that may be
occurring with the pPB19 mutant and S. exigua BBMV. The oc-
currence of several binding sites for a Cry toxin can hide the
lack of one binding site which, although present at a low concen-
trations, could be as important for the mode of action as other
more abundant ones. Along the same lines, changes in these toxin
binding sites in the insect would not be reflected in a large change
in binding parameters. Such a situation may have occurred in
strains of Plutella xylostella and S. exigua that are highly resistant
to Cry1Ca, for which binding studies reported just a small change
in binding capacity [17,35]. This theory is supported by the
observation that lack of a cadherin-like receptor in a Cry1A-
resistant strain of Heliothis virescens (YHD2) [36] hardly affects
the detectable binding of Cry1Ab or Cry1Ac in the resistant strain
[37]. Recently, the study of a strain of Pectinophora gossypiella
(AZP-R) resistant to Cry1A toxins revealed that, although a
cadherin-like receptor was mutated and the binding of Cry1Ab
was altered, no differences were detected in the binding of
Cry1Ac toxin [38,39].
In summary, in the present study we have shown how changes in
the primary structure of Cry1Ca can be correlated with changes
in different steps of its mode of action. We showed, for the first
time, a clear correlation between toxin activity and the ability of
the toxin to form oligomers after interaction with target mem-
branes. Our data support a model where both domain II and do-
main III of Cry1Ca are involved in determining insect specificity
through at least two different kinds of interaction: (i) the
interaction of loops 2 and 3 of domain II with presumably a low-
abundance binding site, and (ii) the interaction between residues
541–544 of domain III and a more abundant, second binding site.
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